Meclizine Hydrochloride

Manufacturer
Mylan Institutional Inc.
Effective date
2018-12-13
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
6
Source
legacy-cache
Hydrated at
2026-08-02 00:42:28

Label at a glance#

ProductMeclizine Hydrochloride
Active ingredientMECLIZINE HYDROCHLORIDE
Label structure11 sections

Indications and uses

For the management of nausea and vomiting, and dizziness associated with motion sickness.

Dosage and administration

The initial dose of 25 mg to 50 mg of meclizine hydrochloride tablets should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Chemically, meclizine hydrochloride, USP is 1-( p-Chloro-α-phenylbenzyl)-4-( m-methylbenzyl) piperazine dihydrochloride monohydrate. The molecular weight is 481.88 g/mole. It has the following structural formula:

Meclizine Structural Formula
Meclizine Structural Formula

Meclizine hydrochloride tablets, USP are available in two different strengths, 12.5 mg and 25 mg.

Inert ingredients for the tablets are: anhydrous lactose, colloidal silicon dioxide, crospovidone, magnesium stearate and microcrystalline cellulose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Meclizine hydrochloride is an antihistamine that shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum.

Pharmacokinetics

PHARMACOKINETICS SECTION

The available pharmacokinetic information for meclizine following oral administration has been summarized from published literature.

Absorption

SPL UNCLASSIFIED SECTION

Meclizine is absorbed after oral administration with maximum plasma concentrations reaching at a median T max value of 3 hours post-dose (range: 1.5 to 6 hours) for the tablet dosage form.

Distribution

SPL UNCLASSIFIED SECTION

Drug distribution characteristics for meclizine in humans are unknown.

Metabolism

SPL UNCLASSIFIED SECTION

The metabolic fate of meclizine in humans is unknown. In an in vitro metabolic study using human hepatic microsome and recombinant CYP enzyme, CYP2D6 was found to be the dominant enzyme for metabolism of meclizine.

The genetic polymorphism of CYP2D6 that results in extensive-, poor-, intermediate- and ultrarapid metabolizer phenotypes could contribute to large inter-individual variability in meclizine exposure.

Elimination

SPL UNCLASSIFIED SECTION

Meclizine has a plasma elimination half-life of about 5 to 6 hours in humans.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the management of nausea and vomiting, and dizziness associated with motion sickness.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Meclizine hydrochloride tablets are contraindicated in individuals who have shown a previous hypersensitivity to it.

WARNINGS

WARNINGS SECTION

Since drowsiness may, on occasion, occur with use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery.

Patients should avoid alcoholic beverages while taking this drug.

Due to its potential anticholinergic action, this drug should be used with caution in patients with asthma, glaucoma, or enlargement of the prostate gland.

PRECAUTIONS

PRECAUTIONS SECTION

Pediatric Use

PEDIATRIC USE SECTION

Clinical studies establishing safety and effectiveness in children have not been done; therefore, usage is not recommended in children under 12 years of age.

Pregnancy Use

PREGNANCY SECTION

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies in rats have shown cleft palates at 25 to 50 times the human dose. Epidemiological studies in pregnant women, however, do not indicate that meclizine increases the risk of abnormalities when administered during pregnancy. Despite the animal findings, it would appear that the possibility of fetal harm is remote. Nevertheless, meclizine, or any other medication, should be used during pregnancy only if clearly necessary.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when meclizine is administered to a nursing woman.

Hepatic Impairment

SPL UNCLASSIFIED SECTION

The effect of hepatic impairment on the pharmacokinetics of meclizine has not been evaluated. As meclizine undergoes metabolism, hepatic impairment may result in increased systemic exposure of the drug. Treatment with meclizine should be administered with caution in patients with hepatic impairment.

Renal Impairment

SPL UNCLASSIFIED SECTION

The effect of renal impairment on the pharmacokinetics of meclizine has not been evaluated. Due to a potential for drug/metabolite accumulation, meclizine should be administered with caution in patients with renal impairment and in the elderly as renal function generally declines with age.

Drug Interactions

DRUG INTERACTIONS SECTION

There may be increased CNS depression when meclizine is administered concurrently with other CNS depressants, including alcohol, tranquilizers, and sedatives (see WARNINGS). Based on in vitro evaluation, meclizine is metabolized by CYP2D6. Therefore there is a possibility for a drug interaction between meclizine and CYP2D6 inhibitors.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Anaphylactoid reaction, drowsiness, dry mouth, headache, fatigue, vomiting and, on rare occasions, blurred vision have been reported.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Motion Sickness

SPL UNCLASSIFIED SECTION

The initial dose of 25 mg to 50 mg of meclizine hydrochloride tablets should be taken one hour prior to travel for protection against motion sickness. Thereafter, the dose may be repeated every 24 hours for the duration of the journey.

HOW SUPPLIED:

HOW SUPPLIED SECTION

Meclizine Hydrochloride Tablets, USP are available containing 12.5 mg and 25 mg of meclizine hydrochloride, USP.

The 12.5 mg tablets are white to off-white, round, unscored tablets debossed with M on one side of the tablet and MCZ over 12 on the other side. They are available as follows:

NDC 51079-423-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).

The 25 mg tablets are white to off-white, round, unscored tablets debossed with M on one side of the tablet and MCZ over 25 on the other side. They are available as follows:

NDC 51079-511-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each).

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Distributed by:
Mylan Institutional Inc.
Rockford, IL 61103 U.S.A.

S-12121 R2
9/17

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 12.5 mg

NDC 51079-423-20

Meclizine
Hydrochloride
Tablets, USP
12.5 mg

100 Tablets (10 x 10)

Each tablet contains:
Meclizine
hydrochloride, USP           12.5 mg

Usual Dosage: See accompanying
prescribing information.

MOTION SICKNESS: 25 mg to 50 mg
daily.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]

Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-12122

Distributed by:

Mylan Institutional Inc.

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Meclizine Hydrochloride 12.5 mg Tablets Unit Carton Label
Meclizine Hydrochloride 12.5 mg Tablets Unit Carton Label
Serialized Unit Carton
Serialized Unit Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

PRINCIPAL DISPLAY PANEL - 25 mg

NDC 51079-511-20

Meclizine
Hydrochloride
Tablets, USP
25 mg

100 Tablets (10 x 10)

Each tablet contains:
Meclizine
hydrochloride, USP         25 mg

Usual Dosage: See accompanying
prescribing information.

MOTION SICKNESS: 25 mg to 50 mg
daily.

Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room
Temperature.]

Manufactured by:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.

Rx only

S-12123

Distributed by:

Mylan Institutional Inc.

Rockford, IL 61103 U.S.A.

This unit dose package is not child resistant.

For institutional use only.

Keep this and all drugs out of the reach of children.

This container provides light-resistance.

See window for lot number and expiration date.

Meclizine Hydrochloride 25 mg Tablets Unit Carton Label
Meclizine Hydrochloride 25 mg Tablets Unit Carton Label
Serialized Unit Carton
Serialized Unit Carton

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51079-423-01EA - Each51079-4238148a4a0-5ab5-4f56-b4dd-b4ba591b537212014-11-05
51079-423-20EA - Each51079-423a01bc7ed-a12f-4d92-afa7-e364ff4cf29c12014-11-05
0378-5485-10EA - Each0378-5485f6697584-fd89-405f-a529-cb0091a6f23812013-02-13
0378-5485-77EA - Each0378-5485392de753-66e3-4801-b3d9-40e9bf2f52d212013-02-13
51079-511-01EA - Each51079-511afa84b83-1b97-4f62-9f99-4f999dae20a512015-04-03
51079-511-20EA - Each51079-5118c9dc1b5-c1b3-409e-b3e9-b296a933c80c12015-04-03
0378-5486-10EA - Each0378-5486d8175ebd-ee68-4f54-a916-f32260a4615e12013-02-13
0378-5486-77EA - Each0378-548621806760-f7d0-4722-951b-18afaadb628512013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
MECLIZINE HYDROCHLORIDEACTIVE INGREDIENTHDP7W44CIO2
MECLIZINEACTIVE MOIETY3L5TQ845702
ANHYDROUS LACTOSEINACTIVE INGREDIENT3SY5LH9PMK2
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61U2
CROSPOVIDONEINACTIVE INGREDIENT68401960MK2
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I302
SILICON DIOXIDEINACTIVE INGREDIENTETJ7Z6XBU42

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 7 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51079-42351079-423-01, 51079-423-20
0378-5485
51079-51151079-511-01, 51079-511-20
0378-5486

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 3 · 137 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, EXTENDED RELEASE / ORAL117 mgExact identifier — unii candidate
39 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET / SUBLINGUAL10 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION / ORAL64 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / TRANSMUCOSAL100 mgExact identifier — unii candidate
39 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GEL / NASAL20 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION, EXTENDED RELEASE / ORAL71 mgExact identifier — unii candidate
39 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4POWDER, FOR SUSPENSION / ORAL2553 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30IMPLANT / INTRAVITREALNAExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / SUBLINGUAL17.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UCAPSULE, DELAYED RELEASE / ORAL366 mgExact identifier — unii candidate
28 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4SUPPOSITORY / RECTAL14 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER, FOR SUSPENSION / ORAL120 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET / SUBLINGUAL128 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, EXTENDED RELEASE / ORAL173 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SYSTEM / INTRAVITREAL0.02 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL47 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, EXTENDED RELEASE / ORAL529 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30WAFER / ORAL66 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, ORALLY DISINTEGRATING / ORAL1800 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, FOR SUSPENSION / ORAL20100 mgExact identifier — unii candidate
28 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET / BUCCAL48 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30PELLET / ORAL24 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30DROPS / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / BUCCAL17.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS375 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30RING / VAGINAL2 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61USUSPENSION / ORAL1600 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE / ORAL256.4 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKGRANULE, FOR SUSPENSION / ORAL3025 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER / ORAL25 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30INHALANT / ORAL0.08 mgExact identifier — unii candidate
39 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4PELLET / ORAL34 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4CREAM / VAGINAL51 mgExact identifier — unii candidate
49 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, DELAYED RELEASE / ORAL1083 mgExact identifier — unii candidate
21 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, FILM COATED / ORAL166 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, DELAYED RELEASE / ORAL1060 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET / ORAL980 mgExact identifier — unii candidate
39 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET / BUCCAL3 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GRANULE, FOR SUSPENSION / ORAL200 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, COATED / ORAL176 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, CHEWABLE, EXTENDED RELEASE / ORAL2 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, FOR SUSPENSION / ORAL220 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GRANULE, DELAYED RELEASE / ORAL3.2 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, EXTENDED RELEASE / ORAL450 mgExact identifier — unii candidate
49 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4TABLET, CHEWABLE / ORAL254 mgExact identifier — unii candidate
49 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / BUCCAL18 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, SUGAR COATED / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, CHEWABLE / ORAL2850 mgExact identifier — unii candidate
21 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4SYSTEM / TRANSDERMAL35 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING / ORAL187 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FILM COATED / ORAL96 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, FOR SUSPENSION / ORAL15 mgExact identifier — unii candidate
21 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, COATED / ORAL560 mgExact identifier — unii candidate
21 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4FILM, EXTENDED RELEASE / TRANSDERMAL616 mgExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30LOZENGE / ORAL420 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, EXTENDED RELEASE / ORAL5119 mgExact identifier — unii candidate
28 equally ranked IID candidates
SILICON DIOXIDESILICON DIOXIDEETJ7Z6XBU4GEL / VAGINAL8 %w/wExact identifier — unii candidate
49 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30IMPLANT / SUBCUTANEOUS0.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30INSERT / VAGINAL69 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, COATED / ORAL184 mgExact identifier — unii candidate
39 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A202640-001MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17
A202640-002MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17
A202640-003MECLIZINE HYDROCHLORIDEMECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 3 matching rows.

Application-product, TE code table
Application-productTE code
A202640-001AA
A202640-002AA
A202640-003AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 135 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17d4dbc9d85df4…
2026-11-14 07:37:172026-10A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17d4dbc9d85df4…
2026-11-14 07:37:172026-10A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17d4dbc9d85df4…
2026-10-15 13:18:302026-09A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17c2088c7a36db…
2026-10-15 13:18:302026-09A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17c2088c7a36db…
2026-10-15 13:18:302026-09A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17c2088c7a36db…
2026-09-14 22:38:342026-08A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-09-14 22:38:342026-08A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1784e616aacf4f…
2026-08-18 06:07:402026-07A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1731067a03dcf5…
2025-08-23 18:47 UTC2025-08A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-176a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-1703ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-1703ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-172680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-175bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-002MECLIZINE HYDROCHLORIDE25MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-003MECLIZINE HYDROCHLORIDE50MGTABLET / ORALAA2012-09-17d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202640-001MECLIZINE HYDROCHLORIDE12.5MGTABLET / ORALAA2012-09-17d06236e962d9…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 80 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A202640-001AA1d4dbc9d85df4…
2026-11-14 07:37:172026-10A202640-002AA1d4dbc9d85df4…
2026-11-14 07:37:172026-10A202640-003AA1d4dbc9d85df4…
2026-10-15 13:18:302026-09A202640-001AA1c2088c7a36db…
2026-10-15 13:18:302026-09A202640-002AA1c2088c7a36db…
2026-10-15 13:18:302026-09A202640-003AA1c2088c7a36db…
2026-09-14 22:38:342026-08A202640-001AA184e616aacf4f…
2026-09-14 22:38:342026-08A202640-002AA184e616aacf4f…
2026-09-14 22:38:342026-08A202640-003AA184e616aacf4f…
2026-08-18 06:07:402026-07A202640-001AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-002AA1caaa826d4ba7…
2026-08-18 06:07:402026-07A202640-003AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A202640-001AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-002AA1011fe1cb6892…
2026-02-19 14:30 UTC2026-02A202640-003AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-001AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-002AA131067a03dcf5…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A202640-003AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A202640-001AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-002AA16a471c1ec25d…
2025-08-23 18:47 UTC2025-08A202640-003AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-001AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-002AA1fd3edfee7708…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A202640-003AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-001AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-002AA1b8a1b40f171c…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A202640-003AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-001AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-002AA103ed91905a0d…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A202640-003AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-001AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-002AA12680178bc6a6…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A202640-003AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-001AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-002AA15bbf6a4d5a75…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A202640-003AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-001AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-002AA1d8e5a09893c0…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A202640-003AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A202640-001AA1d06236e962d9…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
7cef7564-6c72-34a6-e053-2a91aa0ac2b002d9c1dc-a0a2-43b5-bb12-cd8ab03b20612018-12-13Warnings, Adverse reactionsExact identifier
spl id: 7cef7564-6c72-34a6-e053-2a91aa0ac2b0
spl set id: 02d9c1dc-a0a2-43b5-bb12-cd8ab03b2061

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.